Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2010. The document serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs), specifically detailing the granting of share-based awards on February 22, 2010, and the vesting or lapsing of prior awards.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity figures for the company. The only financial data points present relate to executive compensation metrics:
- Share Prices: Ordinary shares closed at £12.035 and ADSs at US$37.32 on February 22, 2010. A separate closing price of £12.35 was used for the Deferred Annual Bonus Plan on February 19, 2010.
- Option Prices: Lapsed 2007 options had an exercise price of £14.88 (or US$58.00 for ADSs).
- Deferred Bonus: CEO Andrew Witty deferred a gross bonus of £300,000.
Material Changes and Transactions
The filing details significant changes in executive equity compensation:
- New Awards (2009 Performance Share Plan): On February 22, 2010, awards were granted to Executive Directors and PDMRs. Vesting is contingent on Total Shareholder Return (TSR) relative to a comparator group of 10 global pharmaceutical companies and Adjusted Free Cash Flow targets ranging from £17.3 billion to £20.5 billion.
- New Awards (2009 Deferred Annual Bonus Plan): CEO Andrew Witty and CFO John Heslop were eligible. Mr. Witty deferred £300,000 of his 2009 bonus into shares, with matching shares contingent on TSR performance.
- Lapsed Awards: Share options granted in 2007 to Executive Directors and Corporate Executive Team members lapsed because performance conditions were not met by December 31, 2009. This included 195,500 ordinary shares for Mr. Witty and 242,750 for Mr. Heslop.
- Exercisable Awards: Certain 2007 grants to senior executives who were not subject to performance conditions became fully exercisable.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, management commentary on business outlook, or general risk factors. However, it outlines specific performance risks tied to executive compensation:
- TSR Risk: No awards will vest if the company's TSR ranks below the median of the comparator group. Vesting scales from 30% at the median to 100% at the 3rd rank or above.
- Cash Flow Risk: Adjusted Free Cash Flow awards vest on a straight-line basis between a threshold of £17.3 billion (25% vesting) and a maximum of £20.5 billion (100% vesting).
Key Facts for Investor Verification
- Verify the company's Adjusted Free Cash Flow performance against the £17.3 billion to £20.5 billion targets set for the 2010-2012/2013 performance periods.
- Monitor the company's TSR ranking relative to the specified comparator group (Abbott, AstraZeneca, BMS, Eli Lilly, J&J, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis) to determine vesting levels for new awards.
- Note that significant equity grants from 2007 lapsed due to unmet performance conditions, indicating potential challenges in meeting prior strategic targets.
- Confirm the specific number of shares potentially vesting for each executive based on the final performance metrics at the end of the three and four-year periods.